Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

OBJECTIVE To examine the safety and cardiovascular (CV) effects of saxagliptin in the predefined elderly (≥65 years) and very elderly (≥75 years) subpopulations of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. RESEARCH DESIGN AND METHODS Individuals ≥40 years (n = 16,492; elderly, n = 8,561; very elderly, n = 2,330) with HbA1c ≥6.5% (47.5 mmol/mol) and ≤12.0% (107.7 mmol/mol) were randomized (1:1) to saxagliptin (5 or 2.5 mg daily) or placebo in a double-blind trial for a median follow-up of 2.1 years. RESULTS The hazard ratio (HR) for the comparison of saxagliptin versus placebo for the primary end point (composite of CV mortality, myocardial infarction, or ischemic stroke) was 0.92 for elderly patients vs. 1.15 for patients <65 years (P = 0.06) and 0.95 for very elderly patients. The HRs for the secondary composite end points in the entire cohort, elderly cohort, and very elderly cohort were similar. Although saxagliptin increased the risk of hospitalization for heart failure in the overall saxagliptin population, there was no age-based treatment interaction (P = 0.76 for elderly patients vs. those <65 years; P = 0.34 for very elderly patients vs. those <75 years). Among saxagliptin-treated individuals with baseline HbA1c ≥7.6% (59.6 mmol/mol), the mean change from baseline HbA1c at 2 years was −0.69%, −0.64%, −0.66%, and −0.66% for those ≥65, <65, ≥75, and <75 years old, respectively. The incidence of overall adverse events (AEs) and serious AEs was similar between saxagliptin and placebo in all cohorts; however, hypoglycemic events were higher for saxagliptin versus placebo regardless of age. CONCLUSIONS The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. AEs and serious AEs as well as glycemic efficacy of saxagliptin in elderly patients are similar to those found in younger patients.

[1]  N. Marx,et al.  [Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial]. , 2015, Deutsche medizinische Wochenschrift.

[2]  S. Schwartz.  Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. , 2010, The American journal of geriatric pharmacotherapy.

[3]  A. Morris,et al.  Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. , 2003, Diabetes care.

[4]  N. Xu,et al.  The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. , 2010, Clinical therapeutics.

[5]  B. Goldstein,et al.  Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies , 2013, Diabetes Therapy.

[6]  Ross T Tsuyuki,et al.  Type 2 diabetes mellitus management in Canada: is it improving? , 2013, Canadian journal of diabetes.

[7]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[8]  Deepak L. Bhatt,et al.  Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial , 2013, Diabetes/metabolism research and reviews.

[9]  K. Lundbaek,et al.  European Association for the study of diabetes , 1969, Diabetologia.

[10]  J. Rosenstock,et al.  Management of Type 2 Diabetes in Treatment-Naive Elderly Patients , 2007, Diabetes Care.

[11]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[12]  Nathaniel Clark,et al.  Diabetes in Older Adults , 2012, Diabetes Care.

[13]  Donna K Arnett,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. , 2014, Journal of the American College of Cardiology.

[14]  Jennifer Y. Liu,et al.  Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. , 2014, JAMA internal medicine.

[15]  Deepak L. Bhatt,et al.  The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.

[16]  R. Frederich,et al.  Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus , 2013, Clinical interventions in aging.

[17]  M. Engelgau,et al.  Complications of diabetes in elderly people , 2002, BMJ : British Medical Journal.

[18]  G. Booth,et al.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Methods. , 2013, Canadian journal of diabetes.

[19]  A. Tasneem,et al.  Are current clinical trials in diabetes addressing important issues in diabetes care? , 2013, Diabetologia.

[20]  D. Matthews,et al.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[21]  S. Saydah,et al.  The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010 , 2013, Diabetes Care.

[22]  A. Cruz-Jentoft,et al.  Exclusion of Older Adults from Ongoing Clinical Trials About Type 2 Diabetes Mellitus , 2013, Journal of the American Geriatrics Society.

[23]  N. Iqbal,et al.  Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus , 2014, Diabetes/metabolism research and reviews.

[24]  H. Rodbard,et al.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[25]  A. Sicras-Mainar,et al.  Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly , 2014, Drug design, development and therapy.

[26]  J. Rosenstock,et al.  Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus , 2011, Current medical research and opinion.

[27]  H. Woerle,et al.  Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[28]  A. Cheng.  Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. , 2013, Canadian journal of diabetes.

[29]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[30]  R. Pratley,et al.  Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies , 2009, Journal of the American Geriatrics Society.

[31]  R. Califf,et al.  Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. , 2013, American heart journal.

[32]  Michael E. Miller,et al.  Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial , 2014, Diabetes Care.

[33]  Lawrence A Leiter,et al.  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee , 2013 .

[34]  R. Pratley,et al.  Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. , 2009, The American journal of medicine.

[35]  S. Dejager,et al.  Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials , 2011, Diabetes, obesity & metabolism.

[36]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[37]  M. Monami,et al.  Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials , 2011, Current medical research and opinion.

[38]  N. Tennagels,et al.  Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats , 2013, Diabetologia.

[39]  Medha N Munshi,et al.  Frequent hypoglycemia among elderly patients with poor glycemic control. , 2011, Archives of internal medicine.

[40]  A. Sinclair,et al.  Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. , 2012, Journal of the American Medical Directors Association.

[41]  Richard A. Goodman,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. , 2014, Circulation.

[42]  Canary Wharf,et al.  Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus , 2010 .

[43]  B. Charbonnel,et al.  Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy , 2013, Clinical Drug Investigation.

[44]  N. Barzilai,et al.  Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial , 2011, Current medical research and opinion.

[45]  M. Monami,et al.  Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.

[46]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.